Financials in USD. Standardized financial statements.
A compact view of how Singular Genomics Systems, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue? | $2.91M | $765,000 | $0 | $0 | $0 |
| Revenue Growth? | +280.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.47M | $789,000 | $1.13M | $639,000 | $350,000 |
| Gross Profit? | -$558,000 | -$24,000 | -$1.13M | -$639,000 | -$350,000 |
| Gross Margin? | -19.2% | -3.1% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $102.24M | $93.46M | $61.28M | $27.53M | $12.77M |
| Operating Income? | -$102.80M | -$93.49M | -$61.28M | -$27.53M | -$12.77M |
| EBITDA? | -$86.50M | -$84.08M | -$96.79M | -$26.59M | -$11.96M |
| Income Before Tax | -$94.82M | -$90.88M | -$98.77M | -$27.95M | -$12.32M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$94.82M | -$88.27M | -$98.89M | -$28.66M | -$12.34M |
| EPS? | $-39.08 | $-37.22 | $-40.95 | $-12.41 | $-5.34 |
| Diluted EPS? | $-39.08 | $-37.22 | $-40.95 | $-12.41 | $-5.34 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality